Atley Solutions has developed the Atley C100, the first automated production module for purifying astatine-211 and synthesizing astatine-based radiopharmaceuticals, enabling efficient and scalable manufacturing. This technology addresses the need for standardized production processes in targeted alpha therapy, facilitating the development of less toxic cancer treatments.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CVFounders
Product
Problem
The development of targeted alpha therapies using astatine-211 (At-211) is hindered by the lack of specialized, automated equipment for efficient and scalable production and purification of the radioisotope and synthesis of corresponding radiopharmaceuticals. Traditional methods often lack the standardization needed for clinical translation and commercial manufacturing.
Solution
Atley Solutions provides the Atley C100, the first commercially available, automated production module designed for purifying At-211 from cyclotron targets and synthesizing At-211-based radiopharmaceuticals. The Atley C100 integrates At-211 purification and radiopharmaceutical synthesis into a single platform, streamlining the manufacturing process. This platform enables researchers and drug developers to overcome key obstacles in At-211 radiopharmaceutical development, facilitating the transition from scientific research to clinical applications. The Atley C100 is designed for reliable and scalable production, supporting both non-clinical R&D and full-scale commercial rollout of At-211 radiopharmaceuticals. By automating these processes, Atley Solutions enables the development of more precise cancer treatments with minimal impact on healthy tissue.
Target Audience
The primary target audience includes researchers, drug developers, and isotope manufacturers involved in targeted alpha therapy and radiopharmaceutical development, as well as clinical sites focused on nuclear medicine and oncology.
Features
- Automated purification of At-211 from irradiated cyclotron targets via dry distillation
- Automated synthesis and purification of At-211-based radiopharmaceuticals
- Integrated platform for both At-211 purification and radiopharmaceutical synthesis
- CE marking & CB certificate of compliance to IEC 61010-1
- At-211 purification yield: >80% (n.d.c.)
- At-211 purification time: <30 minutes
- GMP-compliant design for clinical and commercial manufacturing
- Platform technology adaptable for multiple At-211 radiopharmaceuticals targeting different cancer indications